. 2019 Jul 29;38(3):831–843. doi: 10.1007/s10637-019-00840-1

Table 1.

Demographics and baseline characteristics

Characteristics	Dose Escalation (n = 39)	Dose Expansion (n = 68)
Median (range) age, years	64 (41–84)	64 (36–82)
Sex, n (%)
Men Women	26 (67) 13 (33)	27 (40) 41 (60)
Race, n (%)
White Black Asian Other	34 (87) 3 (8) 2 (5) 0	60 (88) 2 (3) 5 (7) 1 (1)
Primary tumor type, n (%)
Soft tissue sarcoma Liposarcoma Breast carcinoma Multiple myeloma Glioblastoma multiforme Colon carcinoma Non–small-cell lung carcinoma Head and neck carcinoma Thyroid carcinoma Pancreatic carcinoma Melanoma Salivary gland carcinoma Other	9 (23) 0 1 (3) 0 0 4 (10) 4 (10) 2 (5) 2 (5) 2 (5) 2 (5) 3 (8) 10 (26) ^a	19 (28) 5 (7) 12 (18) 10 (15) 10 (15) 1 (1) 2 (3) 0 0 1 (1) 0 2 (3) 11 (16) ^b
ECOG performance status, n (%)
0 1 2	14 (36) 23 (59) 2 (5)	16 (24) 48 (71) 4 (6)
Prior lines of anticancer therapy, n (%)
0 1 2 ≥3	2 (5) 2 (5) 8 (21) 27 (69)	6 (9) 4 (6) 9 (13) 49 (72)
Prior lines of radiotherapy, n (%)
0 1 2 ≥3	17 (44) 9 (23) 6 (15) 7 (18)	29 (43) 25 (37) 9 (13) 5 (7)

Characteristics

Dose Escalation
(n = 39)

Dose Expansion
(n = 68)

Median (range) age, years

64 (41–84)

64 (36–82)

Sex, n (%)

Men

Women

26 (67)

13 (33)

27 (40)

41 (60)

Race, n (%)

White

Black

Asian

Other

34 (87)

3 (8)

2 (5)

60 (88)

2 (3)

5 (7)

1 (1)

Primary tumor type, n (%)

Soft tissue sarcoma

Liposarcoma

Breast carcinoma

Multiple myeloma

Glioblastoma multiforme

Colon carcinoma

Non–small-cell lung carcinoma

Head and neck carcinoma

Thyroid carcinoma

Pancreatic carcinoma

Melanoma

Salivary gland carcinoma

Other

9 (23)

1 (3)

4 (10)

2 (5)

3 (8)

10 (26) ^a

19 (28)

5 (7)

12 (18)

10 (15)

1 (1)

2 (3)

1 (1)

2 (3)

11 (16) ^b

ECOG performance status, n (%)

14 (36)

23 (59)

2 (5)

16 (24)

48 (71)

4 (6)

Prior lines of anticancer therapy, n (%)

≥3

2 (5)

8 (21)

27 (69)

6 (9)

4 (6)

9 (13)

49 (72)

Prior lines of radiotherapy, n (%)

≥3

17 (44)

9 (23)

6 (15)

7 (18)

29 (43)

25 (37)

9 (13)

5 (7)

ECOG, Eastern Cooperative Oncology Group

^aIncludes renal cell tumor (n = 2) and n = 1 each of mesothelioma, neuroendocrine cancer, rectal carcinoma, prostate cancer, neuroendocrine carcinoid, cholangiocarcinoma, esophageal cancer, and granular cell tumor

^bIncludes unknown (n = 2) and n = 1 each of bone tumor, cardia carcinoma, cholangiocarcinoma, endometrial cancer, ileal cancer, osteosarcoma, prostate cancer, squamous lung cancer, and renal cell cancer